CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

Ajay S. Behl, PhD
Published: Tuesday, Jul 19, 2016


Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with metastatic castration-resistant prostate cancer (mCRPC) following treatment with abiraterone acetate (Zytiga) plus prednisone.

These events were observed in comparison with patients who were treated with enzalutamide (Xtandi), Behl explains. This study is part of a larger investigation that is seeking to understand the differences between oral therapies used to treat mCRPC, including abiraterone and enzalutamide.

Results showed that patients who were treated with enzalutamide experienced more CNS events and fatigue compared with patients in the abiraterone and prednisone arm, Behl says.
SELECTED
LANGUAGE

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with metastatic castration-resistant prostate cancer (mCRPC) following treatment with abiraterone acetate (Zytiga) plus prednisone.

These events were observed in comparison with patients who were treated with enzalutamide (Xtandi), Behl explains. This study is part of a larger investigation that is seeking to understand the differences between oral therapies used to treat mCRPC, including abiraterone and enzalutamide.

Results showed that patients who were treated with enzalutamide experienced more CNS events and fatigue compared with patients in the abiraterone and prednisone arm, Behl says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x